Novel oral anticoagulants versus vitamin K antagonists in transcatheter aortic valve replacement treated patients—Patients' vulnerability still matters

Current meta‐analysis suggests that outcomes with novel oral anticoagulants (NOACs) do not significantly differ compared to vitamin K antagonists (VKAs) after transcatheter aortic valve replacement (TAVR) in patients with atrial fibrillation (AF), in particular, NOACs failed to demonstrate a better...

Descripción completa

Detalles Bibliográficos
Autores principales: Tarantini, Giuseppe, Fraccaro, Chiara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Valvular and Structural Heart Diseases
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9544356/
https://www.ncbi.nlm.nih.gov/pubmed/35674104
http://dx.doi.org/10.1002/ccd.30235
_version_ 1784804579013033984
author Tarantini, Giuseppe
Fraccaro, Chiara
author_facet Tarantini, Giuseppe
Fraccaro, Chiara
author_sort Tarantini, Giuseppe
collection PubMed
description Current meta‐analysis suggests that outcomes with novel oral anticoagulants (NOACs) do not significantly differ compared to vitamin K antagonists (VKAs) after transcatheter aortic valve replacement (TAVR) in patients with atrial fibrillation (AF), in particular, NOACs failed to demonstrate a better safety profile than VKAs in this clinical setting. Accordingly, the choice between NOACs and VKAs in AF patients after TAVR is left to clinical judgment. Future large‐scale clinical trials are warranted to establish a clinically superior anticoagulant regime in this clinical setting, based on risk profile and need for concomitant antiplatelet therapy.
format Online
Article
Text
id pubmed-9544356
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-95443562022-10-14 Novel oral anticoagulants versus vitamin K antagonists in transcatheter aortic valve replacement treated patients—Patients' vulnerability still matters Tarantini, Giuseppe Fraccaro, Chiara Catheter Cardiovasc Interv Valvular and Structural Heart Diseases Current meta‐analysis suggests that outcomes with novel oral anticoagulants (NOACs) do not significantly differ compared to vitamin K antagonists (VKAs) after transcatheter aortic valve replacement (TAVR) in patients with atrial fibrillation (AF), in particular, NOACs failed to demonstrate a better safety profile than VKAs in this clinical setting. Accordingly, the choice between NOACs and VKAs in AF patients after TAVR is left to clinical judgment. Future large‐scale clinical trials are warranted to establish a clinically superior anticoagulant regime in this clinical setting, based on risk profile and need for concomitant antiplatelet therapy. John Wiley and Sons Inc. 2022-06-08 2022-06-01 /pmc/articles/PMC9544356/ /pubmed/35674104 http://dx.doi.org/10.1002/ccd.30235 Text en © 2022 The Authors. Catheterization and Cardiovascular Interventions published by Wiley Periodicals LLC. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Valvular and Structural Heart Diseases
Tarantini, Giuseppe
Fraccaro, Chiara
Novel oral anticoagulants versus vitamin K antagonists in transcatheter aortic valve replacement treated patients—Patients' vulnerability still matters
title Novel oral anticoagulants versus vitamin K antagonists in transcatheter aortic valve replacement treated patients—Patients' vulnerability still matters
title_full Novel oral anticoagulants versus vitamin K antagonists in transcatheter aortic valve replacement treated patients—Patients' vulnerability still matters
title_fullStr Novel oral anticoagulants versus vitamin K antagonists in transcatheter aortic valve replacement treated patients—Patients' vulnerability still matters
title_full_unstemmed Novel oral anticoagulants versus vitamin K antagonists in transcatheter aortic valve replacement treated patients—Patients' vulnerability still matters
title_short Novel oral anticoagulants versus vitamin K antagonists in transcatheter aortic valve replacement treated patients—Patients' vulnerability still matters
title_sort novel oral anticoagulants versus vitamin k antagonists in transcatheter aortic valve replacement treated patients—patients' vulnerability still matters
topic Valvular and Structural Heart Diseases
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9544356/
https://www.ncbi.nlm.nih.gov/pubmed/35674104
http://dx.doi.org/10.1002/ccd.30235
work_keys_str_mv AT tarantinigiuseppe noveloralanticoagulantsversusvitaminkantagonistsintranscatheteraorticvalvereplacementtreatedpatientspatientsvulnerabilitystillmatters
AT fraccarochiara noveloralanticoagulantsversusvitaminkantagonistsintranscatheteraorticvalvereplacementtreatedpatientspatientsvulnerabilitystillmatters

Ejemplares similares